Advertising Mental Health Services That Builds Trust

Tier One: Descriptive Service and Credential Claims

The foundational level of claims describes the treatment center’s basic attributes and staff qualifications. Examples include “licensed by the state as a residential SUD facility,” “Joint Commission accredited since 2016,” “in-network with Aetna and Cigna,” or “psychiatrists board-certified in addiction medicine.” These are verifiable facts, substantiated by documents such as license numbers, accreditation certificates, signed payer contracts, or National Provider Identifier records.

The FTC still expects these claims to be truthful and non-misleading, emphasizing the “net impression” a reasonable consumer receives ³. For instance, a campaign featuring only one MD among fifteen staff members, while referring to them as “our doctors,” creates an implied claim that could be misleading, even if each individual word is accurate.

Descriptive claims are generally the safest for paid search headlines, display creative, and location pages, and they typically face less friction in legal review due to their documentary substantiation.

Tier Two: Process and Modality Claims

This intermediate tier details the program’s internal operations and therapeutic approaches. Claims like “evidence-based CBT and DBT delivered by licensed clinicians,” “medication-assisted treatment with buprenorphine and naltrexone,” “trauma-focused therapy in a 90-day residential setting,” and “family therapy included at no additional cost” describe the intervention itself, not its outcomes.

The FTC requires competent and reliable scientific evidence for health-related claims, a standard that extends to process claims because they imply clinical appropriateness for the marketed condition ². Substantiation typically involves published clinical literature supporting the modality for the target population, alongside internal documentation confirming the program’s actual delivery of the described services. For example, an ad promoting EMDR for PTSD would require evidence of clinician credentialing and the specific treatment protocol used.

Process claims can subtly lead to implied outcome claims. The term “evidence-based” describes a modality, not a guarantee of recovery, and creative reviewers should ensure adjacent copy does not transform this into a results promise.

Tier Three: Outcome, Recovery, and Superiority Claims

This highest tier carries the most enforcement risk for marketing leaders. Claims such as completion rates, sobriety percentages, relapse-prevention figures, “the leading dual-diagnosis program in the Southeast,” or “most patients return to work within 60 days” are considered outcome or superiority claims. The FTC explicitly states that these categories require the most robust competent and reliable scientific evidence, demanding solid proof before publication ². Implied claims are treated with the same scrutiny as express ones; a headline like “Get your life back” next to a smiling alumnus can create an outcome promise even without explicit numbers ³.

Substantiation for Tier Three claims is significantly more demanding. A published outcome percentage requires a clearly defined denominator, a specific measurement window, a detailed follow-up methodology, and disclosure of the studied population. Superiority claims necessitate head-to-head comparative data, not just internal perceptions. If evidence at this standard is unavailable, the claim must either be removed or rephrased to a lower tier.

The table below summarizes the escalating evidence burden applied by the FTC across these claim tiers:

CMOs who integrate this ladder into their creative brief can streamline legal review processes by preventing copywriters from drafting Tier Three headlines that lack sufficient evidentiary support.

Where Meta Pixel and GA4 Cross the HIPAA Line

While a Meta Pixel is standard on a retail website, its function changes significantly when it fires on a treatment center’s fentanyl detox page. The HHS Office for Civil Rights has clarified that tracking technology obligations depend on the data transmitted and the context of collection. Information that includes an identifier combined with an inference about a person’s health condition or treatment interest can qualify as PHI ¹.

The distinction becomes clearer when considering different page types:

• On unauthenticated marketing pages, generic pageviews of a homepage or careers page typically fall outside the PHI boundary.
• However, the same pixel on a service-line page for opioid use disorder, a symptom self-assessment, or any URL indicating interest in a specific condition can transmit an identifier linked to a treatment inference, which HHS has specifically highlighted as problematic ¹.
• On authenticated intake or patient portal pages, tracking generally accesses PHI and must either be covered by a Business Associate Agreement (BAA) or removed ¹.

For SUD service lines, 42 CFR Part 2 imposes even stricter standards, as the mere record identifies the person as having sought SUD care ⁶.

Call Tracking, VOB Forms, and Vendor Configuration

Call tracking frequently creates an unnoticed intersection between marketing infrastructure and clinical data. A dynamic number insertion platform that records, transcribes, and feeds keywords into an ad platform captures conversations where callers often mention substances, diagnoses, prescriptions, or prior treatment episodes. If this content leaves the treatment center’s environment and reaches a vendor without a Business Associate Agreement, the HHS OCR’s tracking guidance considers this disclosure equivalent to a pixel firing on an authenticated page ¹.

Verification of Benefits (VOB) forms present a similar challenge. The information marketing teams collect for insurance verification—such as name, date of birth, member ID, substance of concern, and requested level of care—is precisely what a Part 2 program is obligated to protect from redisclosure ⁶. When this data flows through a form vendor, CRM, and lead-routing tool, each transfer requires a written agreement and configuration review, rather than assuming a simple checkbox on the form suffices.

Practical configuration solutions include:

• Server-side tagging
• Hashing data before transmission
• Disabling automatic transcription for SUD-related calls
• Deactivating ad-platform audience uploads that use PHI as a key identifier

Non-HIPAA Infrastructure: Quizzes, Self-Assessments, and the FTC Health Breach Notification Rule

Marketing teams sometimes mistakenly believe that symptom quizzes developed by external vendors are outside the compliance scope because the treatment center doesn’t host the database. The FTC’s Health Breach Notification Rule addresses this gap. This rule can apply to organizations not covered by HIPAA if they handle identifiable health information, and its July 2024 amendments explicitly brought health apps and similar technologies within its purview ⁴.

A depression screener, an addiction self-assessment, a chatbot inquiring about drinking frequency, or a lead magnet collecting symptoms in exchange for a downloadable guide can all generate identifiable health information. If a vendor shares this data with an ad platform without clear user consent, the FTC has deemed such transfers unauthorized disclosures, requiring notification to affected individuals, the agency, and sometimes the media ⁴.

CMOs should inventory all quizzes, calculators, chatbots, and gated assessments operating under their brand, verify what each vendor transmits downstream, and ensure privacy notices accurately reflect the actual data flow.

Compensation Structures and the Risk Signals They Send

The compensation structure within a marketing vendor contract is often one of the first documents examined by federal or state investigators when a treatment center faces scrutiny. The DOJ’s Rapid Response Strike Force has specifically targeted schemes involving illegal financial incentives for patient enrollment, medically unnecessary services, and patient recruiters, often referred to as body brokers ⁷. California Business and Professions Code section 650 generally prohibits compensation or inducements for patient referrals but allows for third-party advertising and internet-based information services, provided the provider does not recommend a specific licensee and the fee is proportionate to the service delivered ⁸.

Three primary vendor compensation structures are prevalent in behavioral-health marketing, each signaling a different level of risk:

CMOs drafting or renewing vendor contracts should prioritize flat-fee or scope-based compensation for all patient acquisition activities. It is crucial to document that the fee reflects the market value of the work performed and to prohibit any bonuses tied to admission counts. State laws add another layer of complexity; a structure permissible in one jurisdiction may create exposure in another ⁸.

If a CMO Oversees Multiple Facilities or Brands

Marketing leaders managing a portfolio of facilities or a multi-brand parent company face different pressures than single-site CMOs, which alters the referral-economics analysis. Practices like inter-company lead sharing, shared call centers, and cross-brand retargeting, while appearing operationally efficient, can inadvertently create compensation patterns that the DOJ interprets as illegal recruitment ⁷.

Every portfolio review should address three structural questions:

1. Does any internal transfer price between a shared services entity and an operating facility increase with admissions rather than with the actual cost of services?
2. Does a shared call center route callers to the facility offering the highest internal allocation instead of the most clinically appropriate level of care?
3. Do affiliate or partner brands receive any value—such as traffic, leads, or co-branded creative—contingent on admissions volume flowing back to them?

Portfolio CMOs must document the methodology behind all intercompany allocations, ensure clinical placement decisions are insulated from marketing economics, and verify, state-by-state, that the corporate structure does not transform lawful advertising into compensated referral activity under statutes like California B&P 650 ⁸.